Solar Lighting to Reduce Indoor Air Pollution in Rural Uganda

December 5, 2020 updated by: Peggy S Lai, Massachusetts General Hospital

Solar Lighting Intervention Trial to Reduce Indoor Air Pollution and Improve Adult Respiratory Health in Rural Uganda

This study evaluates the impact of a solar lighting system on kerosene lamp use, levels of indoor air pollution, and health in women living in rural Uganda. Half of the participants will receive the lighting systems immediately, while the other half will receive them after an 18 month delay.

Study Overview

Detailed Description

One fifth of the global population relies on kerosene lamps for lighting, yet few studies have focused on kerosene lighting as a source of indoor air pollution. In our preliminary studies performed in Uganda, we show that homes using solar lighting have much lower levels of indoor air pollution compared to homes using kerosene lighting. The primary goal of this study is to determine the extent to which solar lighting will reduce kerosene use and indoor air pollution in rural Uganda, whether this intervention improves lung health, and to identify the role bacteria in our gut have on determining whether or not people will get sick from indoor air pollution.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Mbarara, Uganda
        • Mbarara University of Science and Technology
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women living in Nyakabare Parish, Uganda with no prior history of chronic lung disease

Exclusion Criteria:

  • Current active tuberculosis in any family member

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control (usual lighting)
Participants will continue to use their usual lighting sources.
Experimental: Intervention (solar lighting)
Participants will receive an indoor solar lighting system
consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fine particulate matter (PM2.5) and Black Carbon
Time Frame: 48 hour
Sampling for PM2.5 and Black Carbon over 48 hours will be collected
48 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daily use of solar lighting system (hours per day)
Time Frame: baseline, 3 months, 6 months, 12 months after the intervention
A current monitory is installed as part of the solar lighting system that measures the hours per day each light switch is turned on
baseline, 3 months, 6 months, 12 months after the intervention
Blood pressure
Time Frame: baseline, 3 months, 6 months, 12 months after the intervention
Resting blood pressure
baseline, 3 months, 6 months, 12 months after the intervention
Forced Expiratory Volume in one Second (FEV1)
Time Frame: baseline, 3 months, 6 months, 12 months after the intervention
Pre- and Post- bronchodilator spirometry
baseline, 3 months, 6 months, 12 months after the intervention
Heart rate variability
Time Frame: baseline, 3 months, 6 months, 12 months after the intervention
Resting 10 minute heart rate variability
baseline, 3 months, 6 months, 12 months after the intervention
Stool microbiome
Time Frame: baseline, 3 months, 6 months, 12 months after the intervention
Microbial sequencing of the stool will be performed
baseline, 3 months, 6 months, 12 months after the intervention
Qualitative interviews
Time Frame: Post-intervention
1:1 qualitative interviews will be performed with participants
Post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Peggy S Lai, MD MPH, Massachusetts General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 7, 2018

Primary Completion (Actual)

October 31, 2019

Study Completion (Actual)

October 31, 2020

Study Registration Dates

First Submitted

November 19, 2017

First Submitted That Met QC Criteria

November 19, 2017

First Posted (Actual)

November 22, 2017

Study Record Updates

Last Update Posted (Actual)

December 9, 2020

Last Update Submitted That Met QC Criteria

December 5, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2017P000306/PHS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Solar lighting system

3
Subscribe